Clinical Trials
98 trialsIGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
TREAT-EC
Rutgers, The State University of New Jersey
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
MARACAS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
National Cancer Institute (NCI)
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
ASCEND
UNC Lineberger Comprehensive Cancer Center
Topical Curcumin for HPV Related Cervical Disease
Emory University
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
University of California, San Francisco
MITO END-4
National Cancer Institute, Naples
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Washington University School of Medicine
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT
Ruijin Hospital
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial
New Mexico Cancer Research Alliance
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
University of Maryland, Baltimore
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
RIFT-SSA
Institut d'Investigació Biomèdica de Bellvitge
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
IMMUNE-SAVE
Women's Hospital School Of Medicine Zhejiang University
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Onconic Therapeutics Inc.
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
Zhongnan Hospital
Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
Peking University Third Hospital
A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer
Tongji Hospital
EV-4-EC
Medical College of Wisconsin
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
Sun Yat-sen University
Prospective, Multicenter, Single-Arm, Phase â…¡ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
The First Affiliated Hospital of Zhengzhou University
RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
Asan Medical Center
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Evergreen Therapeutics, Inc.
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer
Women's Hospital School Of Medicine Zhejiang University
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
Weill Medical College of Cornell University
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC
Qilu Hospital of Shandong University
Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer
Sun Yat-sen University
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
Fudan University
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
Tianjin Medical University Cancer Institute and Hospital
RODEO
University College, London